Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Viswanatha

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
American Journal of Hematology|November 5, 2011
TP53 mutations and polymorphisms in primary myelofibrosisSania Raza, David Viswanatha, Lori Frederick, et al.
American Journal of Hematology|June 26, 2024
Null-type SH2B3 mutations are potential drivers in a subset of Ph-negative myeloproliferative neoplasmsXi Zhang, Yi Ding, Peng Li, et al.
The Journal of Molecular Diagnostics : JMD|December 20, 2008
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular PathologyDan Jones, Suzanne Kamel-Reid, David Bahler, et al.
Blood Cancer Journal|July 6, 2022
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive casesMaymona G Abdelmagid, Mark R Litzow, Kristen B McCullough, et al.
Bone Marrow Transplantation|August 20, 2022
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemiaAnmol Baranwal, Ahmad Nanaa, David Viswanatha, et al.
American Journal of Hematology|August 4, 2018
The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDSOmar Alkharabsheh, Aref Al-Kali, Salwa Saadeh, et al.
Human Immunology|March 29, 2024
Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methodsDarren Brow, Hiroko Shike, Jasmine Kendrick, et al.
Frontiers in Oncology|March 17, 2022
<i>DNMT3A</i> R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML TransformationMajd Jawad, Michelle Afkhami, Yi Ding, et al.
Leukemia Research|December 31, 2022
Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort studyStephanie L Pritzl, Mark Gurney, Talha Badar, et al.
Blood Advances|July 23, 2024
Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experienceSteven Tessier, Rong He, Patricia Greipp, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|November 5, 2011
TP53 mutations and polymorphisms in primary myelofibrosisSania Raza, David Viswanatha, Lori Frederick, et al.
American Journal of Hematology|June 26, 2024
Null-type SH2B3 mutations are potential drivers in a subset of Ph-negative myeloproliferative neoplasmsXi Zhang, Yi Ding, Peng Li, et al.
The Journal of Molecular Diagnostics : JMD|December 20, 2008
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular PathologyDan Jones, Suzanne Kamel-Reid, David Bahler, et al.
Blood Cancer Journal|July 6, 2022
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive casesMaymona G Abdelmagid, Mark R Litzow, Kristen B McCullough, et al.
Bone Marrow Transplantation|August 20, 2022
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemiaAnmol Baranwal, Ahmad Nanaa, David Viswanatha, et al.
American Journal of Hematology|August 4, 2018
The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDSOmar Alkharabsheh, Aref Al-Kali, Salwa Saadeh, et al.
Human Immunology|March 29, 2024
Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methodsDarren Brow, Hiroko Shike, Jasmine Kendrick, et al.
Frontiers in Oncology|March 17, 2022
<i>DNMT3A</i> R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML TransformationMajd Jawad, Michelle Afkhami, Yi Ding, et al.
Leukemia Research|December 31, 2022
Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort studyStephanie L Pritzl, Mark Gurney, Talha Badar, et al.
Blood Advances|July 23, 2024
Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experienceSteven Tessier, Rong He, Patricia Greipp, et al.
Pageof 6